Nathalie speaks with Madelaine Haddican, MD., of the Department of Dermatology at Mount Sinai School of Medicine, about the new clinical trials for Clinuvel’s new treatment for vitiligo, Afamelanotide. Dr. Haddican will describe the study and give qualification details for those wishing to participate in the trial.
Here is the basic info given to us by Dr. Haddican:
20 Patients per location will be chosen to participate.
What will take place?
The study is composed of a 6-month treatment period with NB-UVB light treatments, performed 3 times a week, with or without administration of the experimental drug. Thereafter, there will be a 6-month follow-up period with one visit to the Department of Dermatology every 2 months. The entire study will last about 1 year and includes NB-UVB light treatment and 11 visits to the Department of Dermatology.
Participation in the study is free, travel expenses will be reimbursed, and you will be paid $700.
Your information will be kept confidential.
- Must be 18 yrs old or older
- 15% or more vitiligo coverage (1 area of vitiligo that is the size of your hand is considered 1%)
- Medium to dark complexion
- Skin that does not easily burn
- Have had vitiligo for less than 5 years
Locations and Contact Info:
Dept. of Dermatology Mt. Sinai
Rita V. Patel, MD or Madelaine Haddican, MD
5 East 98th Street, 5th Floor
New York, NY 10029
Tel: (212) 241-3288
Oma Agbai, MD
3031 W. Grand Blvd., Suite 800
Detroit, MI 48202
Research Office (313) 916-6964
Kali Ghazali, CRC
5670 Wilshire Blvd, Suite 650
Los Angeles, CA 90036
(323) 467-4389 ext 6